... inflammatory skin disease is a highly promising area for the company because we have a lot of knowledge about the skin. However, we found that…
In Conversation
We are the only CDMO represented in the SMI’s Health Systems Task Force ... This foregrounds our positioning as a strategic partner to pharma and a…
Immuno-oncology has revolutionized cancer therapy, but despite the huge success there has been in the area, there are still many unmet patient needs
Our preclinical data and clinical experience with our pipelines have been highly promising, and we are eager to advance our clinical trials to later stages.
... these different therapeutic platforms are based upon how we can handle these T-cells to attack cancer, and then how we can manage, modify or improve…
The first approval of a regenerative medicine product in Korea was in 2002. Since then, a total of 15 cell and gene therapies, including immunotherapies and…
My hope is that health sector R&D funding, especially towards translational research, will continue to increase in Korea, and we will need to work harder and…
The pandemic has shown the importance of collaboration and that individual actors cannot solve the health problems of today alone
Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm's tireless work to…
We were the first Korean biotech to have independently developed, commercialized, marketed and exported an innovative drug
There is growing interest from capital to invest in diagnostics companies. Within ten years, there is the possibility that this increased support and funding may help…
The pandemic, while tragic, has provided Korean bio-ventures with opportunities to develop and mature
